2021
DOI: 10.4254/wjh.v13.i10.1234
|View full text |Cite
|
Sign up to set email alerts
|

In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?

Abstract: Hepatitis C virus (HCV) is responsible for no less than 71 million people chronically infected and is one of the most frequent indications for liver transplantation worldwide. Despite direct-acting antiviral therapies fuel optimism in controlling HCV infections, there are several obstacles regarding treatment accessibility and reinfection continues to remain a possibility. Indeed, the majority of new HCV infections in developed countries occur in people who inject drugs and are more plausible to get reinfected… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(11 citation statements)
references
References 281 publications
0
11
0
Order By: Relevance
“…However, progress should be made in the development of effective HCV vaccinations. To avoid future viral infections, new research is expected to take advantage of the rapid proliferation of RNA-based vaccines and recombinant vectors utilized in the coronavirus 19 pandemic (35).…”
Section: Discussionmentioning
confidence: 99%
“…However, progress should be made in the development of effective HCV vaccinations. To avoid future viral infections, new research is expected to take advantage of the rapid proliferation of RNA-based vaccines and recombinant vectors utilized in the coronavirus 19 pandemic (35).…”
Section: Discussionmentioning
confidence: 99%
“…Nucleic acid vaccines, including DNA and RNA vaccines, exhibit promising potential in targeting HCV. Nucleic acid vaccines provide a number of potential advantages over conventional vaccines, including the stimulation of both B- and T-cell responses, improved vaccine stability, absence of any infectious agent, and the relative ease of large-scale manufacture [ 144 ]. Moreover, the immune responses induced by nucleic acid vaccines targeted a selected antigen in the pathogen.…”
Section: Hepatitis C Vaccinementioning
confidence: 99%
“…In fact, the biology and immunology of HCV differ significantly from those of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the as-yet unexplored possibility of an HC mRNA-based vaccine could certainly benefit from the experience and developments in the field of RNA-based vaccines against SARS-CoV-2 [ 144 ].…”
Section: Hepatitis C Vaccinementioning
confidence: 99%
“…formulation as mentioned above, demonstrated the ability to elicit elevated levels of IgG antibodies, proinflammatory cytokines, and granzyme B, thereby suggesting its potential as a candidate for an HCV vaccine. A vaccine targeting HBV was created utilizing a BMV approach, whereby the HBV core protein was affixed to either the inner or OM of E. coli [ 40 , 131 ].…”
Section: Advantages and Disadvantages Of Bacterial Drug Delivery Syst...mentioning
confidence: 99%